Gb0139
WebDec 21, 2024 · Rationale High galectin-3 levels predict poor outcomes in patients with COVID-19. Galectin-3 activates monocytes and macrophages which are directly … WebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis; (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 ...
Gb0139
Did you know?
WebApr 26, 2024 · GB0139 is an inhaled small molecule inhibitor of galectin-3 that is administered as a once-daily inhalation via a generic dry powder inhaler. GB0139 is designed to specifically target galectin-3, a main regulator of the fibrosis cascade. WebApr 26, 2024 · GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2024 BOSTON, April 26, 2024 (GLOBE NEWSWIRE ...
WebAug 8, 2024 · Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological … WebApr 11, 2024 · DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2024,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape.
WebFeb 4, 2024 · Detailed Description. This study is designed to evaluate the efficacy and safety of GB0139, a galectin-3 inhibitor, administered by dry powder inhalation over 52 weeks. GB0139, given once per day, will be compared to placebo. GB0139 was … WebMar 15, 2024 · Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its interim review of the company’s Phase 2b GALACTIC-1 study of GB0139 for the treatment of Idiopathic …
WebApr 14, 2024 · It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life ...
WebJan 10, 2024 · GB0139. inhaled galectin-3 inhibitor. Ph. II for IPF + Ph. Ib/IIa for COVID-19 pneumonitis. synthetic galactoside derivative. medRxiv, January 10, 2024. Galecto, Inc., … dnd monk attributescreate directory if not exists bashWebAug 8, 2024 · Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological … dnd monk character sheetWebDec 31, 2024 · Our lead product candidate is an inhaled galectin-3 modulator, GB0139, currently in a Phase 2b study for the treatment of idiopathic pulmonary fibrosis. Our pipeline also includes an orally active galectin-3 inhibitor, GB1211, that is expected to be part of (i) a phase 2 trial for the potential treatment of NSCLC in combination with an anti-PD1 ... create directory if not exists golangWebApr 26, 2024 · GB0139 is designed to specifically target galectin-3, a main regulator of the fibrosis cascade. The overexpression of galectin-3 is ubiquitous in fibrotic tissue, … create directory if not exists nodejsWebGB0139, an inhaled small molecule inhibitor of galectin-3, a protein known to play a central role in fibrosis in several organs, has received Orphan Drug Designation (ODD) from both the US FDA and the EMA for the treatment of IPF. dnd monk characterWebHCPCS Code: G0239. HCPCS Code Description: Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or … dnd monk concept art